Molecular markers to aid in early diagnosis of pancreatic cancer Michael Goggins, MD Professor of Pathology, Medicine and Oncology Johns Hopkins Medical.

Slides:



Advertisements
Similar presentations
Rachel Patel Radu Reit Taylor Guffey Harry Han Shelby Hassberger Daniel Kim Lauren Morgan Elizabeth Morris.
Advertisements

BME 1300 Problem 1 Newstetter Group Haval Amedi Mollie Bryan Eric Flynn Peymaun Ghafouri-Kia Ryan Gleber Walter Kim Chelsea Proffitt Laini Whitton.
Department of Pathology
Great Debates & Updates in GI Malignancies
Cystic Neoplasms of the Pancreas
Al-Qassim University Faculty of Medicine Phase II – Year III GIT Block (CMD332) EXOCRINE PANCREASE Lecture Dr. Gamal Hamra Wednesday 01/12/1430 (18/11/2009)
Multitarget Stool DNA Testing for Colorectal-Cancer Screening NEJM April 3, 2014 Vol 3 Imperiale, T.F. et al Presented by Melissa Spera, MD.
Update on Cholangiocarcinoma: What we have learned from the International Hepatobiliary Neoplasia Biorepository Roon Chaiteerakij, MD Mayo Clinic, Rochester,
By AMGAD FOUAD Professor Of Surgery Gastroenterology Center Gastroenterology Center Mansoura University. Factors Affecting survival after pancreatico.
New-onset Diabetes is a Marker of Pancreatic Cancer Suresh T. Chari, MD Professor of Medicine Miles and Fitterman Center for Digestive Disease Mayo Clinic.
Martina Rastovac Mentor: A. Žmegač Horvat. Actor Patrick Swayze died after a 20-month battle with pancreatic cancer. He was 57.Patrick Swayze.
Pancreas Cancer Nimisha K. Parekh, MD, MPH
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Diseases of the Pancreas. 67 y old male with loss of appetite, gradual weight loss and dyspepsia. Recent onset of jaundice and dark urine.
A significant increase in the incidence of endometrial cancer. This increased incidence of endometrial cancer has been widely interpreted to be a result.
Journal Reading Presented by Dr. 陳志榮. An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal.
IgG4 Pancreatitis Dr Chan Lok Lam Laura United Christian Hospital JHSGR 6 th Aug, 2011.
Early diagnosis of pancreatic cancer Moderators: Banke Agarwal, MD David Linehan, MD Panelists: Suresh Chari, MD Michael Goggins, MD David Whitcombe, MD.
Genetic and Molecular Epidemiology
Endoscopic Ultrasound in Chronic Pancreatitis
© Dr Whitcomb Familial Pancreatic Cancer Families (and other high-risk people) David C Whitcomb MD PhD Giant Eagle Foundation Professor of Cancer Genetics.
ERIC TRAWICK EUS CONFERENCE JUNE 2011 Pancreas Cyst.
Erasmus Medical Center, Rotterdam Marco Bruno Surveillance of Individuals At High Risk For Developing Pancreatic Cancer.
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #1 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
Atoosa Adibi MD. Department of Radiology Isfahan University Of Medical Sciences.
Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.
INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM OF THE PANCREAS:
PANCREATIC CANCER.
1 Differential Diagnosis of Neoplastic Pancreatic Cysts: The Role of EUS with Guided FNA Erwin M. Santo, MD Head, Invasive Endoscopy Unit Dep. of Gastroenterology.
1 Jack London, PhD Research Professor, Cancer Biology Thomas Jefferson University Informatics Shared Resource Director Sidney Kimmel Cancer Center at Jefferson.
Laparoscopic Pancreatectomy Attila Nakeeb, M.D., F.A.C.S. Department of Surgery Indiana University School of Medicine 7th Annual Symposium on Gastrointestinal.
Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.
Pancreatic Tumors Unknown Cases.
Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,
Role of EUS in pancreato- biliary Disorders A Aljebreen M.D, FRCPC Gastroenterology Division, KKUH, King Saud University EUS meeting, KFMC, Dec 16, 2006.
Cystic lesion of pancreas
Pancreatic Cancer L. Okolicsanyi G. Morana Pancreas Cancer l 2nd most common GI malignancy l 30,000 cases per year in US l 25,000 deaths per year l 4.
Grading And Staging Grading is based on the microscopic features of the cells which compose a tumor and is specific for the tumor type. Staging is based.
1 Differential Diagnosis of Neoplastic Pancreatic Cysts: The Role of EUS with Guided FNA E.M.Santo,Y.Ron,O.Barkay,Y.Kopelman,M.Leshno,S.Marmor Dep. of.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
Dr. Jeyaparvathi Somasundaram
Supplemental Figure 1. A typical KRAS Sanger dye termination sequencing trace for a pancreatic cancer sample. The arrow indicates the mutation site; the.
PGY 101: Chapters 53 & 54 Lisa Spiguel, MD. True or False: The most common cause of chronic pancreatitis in the US is related to gallstones.
CT Colonography vs Colonoscopy for the Detection of Advanced Neoplasia David H. Kim, M.D., Perry J. Pickhardt, M.D., Andrew J. Taylor, M.D., Winifred K.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
Towards Global Eminence K Y U N G H E E U N I V E R S I T Y Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients With Pancreatic.
Pancreatic endoscopy : ROLE Of Endo TOF PET US Pr. René LAUGIER La Timone Hospital,Marseille MEDAMI Alghero, 4 th September 2014.
Genomic Medicine Rebecca Tay Oncology Registrar. What is Genomic Medicine? personalised, precision or stratified medicine.
R2 최하나. INTRODUCTION Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas –Intraductal proliferation of mucin-producing epithelial cells –Cystic.
심 재 준심 재 준 Am J Gastroenterol 2007;102:
Lecture Fifteen Biomedical Engineering for Global Health.
Pancreatic cancer Ayman Hasan Linjawi, MD, FRCSC,
Molecular Markers in Thyroid Disease Yeah or Meh?
Genetics and pathology of pancreatic cancer
Pancreas Cysts : What Do I Do in My Practice??
Cystic Neoplasms of the Pancreas: A Surgical Perspective
Evaluation of the Guidelines for Management of Pancreatic Branch-Duct Intraductal Papillary Mucinous Neoplasm  Raymond S. Tang, Benjamin Weinberg, David.
Age at Diagnosis (years)
Reporting precursors to invasive pancreatic cancer: pancreatic intraepithelial neoplasia, intraductal neoplasms and mucinous cystic neoplasm  Roeland.
Volume 133, Issue 1, Pages (July 2007)
Reporting precursors to invasive pancreatic cancer: pancreatic intraepithelial neoplasia, intraductal neoplasms and mucinous cystic neoplasm  Roeland.
James L. Buxbaum, MD  Clinical Gastroenterology and Hepatology 
Marcia Irene Canto, Michael Goggins, Charles J
Volume 154, Issue 3, Pages (February 2018)
Volume 155, Issue 3, Pages e2 (September 2018)
Marcia Irene Canto, Michael Goggins, Ralph H. Hruban, Gloria M
Cystic Neoplasm of the Pancreas Clinical Review of 60 Cases and Treatment Strategy D.K.Kim, S.I.Noh, J.S.Heo, J.H.Noh, T.S.Sohn, S.J.Kim, S.H.Choi, J.W.Joh,
Early Detection of Pancreatic Cancer: Opportunities and Challenges
Determining Malignant Potential of Intraductal Papillary Mucinous Neoplasm of the Pancreas: CT versus MRI Using Revised 2017 International Consensus Guidelines.
Figure 7b. Complications of pancreatitis mimicking a pancreatic tumor
Presentation transcript:

Molecular markers to aid in early diagnosis of pancreatic cancer Michael Goggins, MD Professor of Pathology, Medicine and Oncology Johns Hopkins Medical Institutions, Baltimore, MD “7th Annual Symposium on Gastrointestinal Cancers " St. Louis, Mo, 9/20/08

Disclosure Dr. Goggins has licensing agreements with Oncomethylome sciences for several DNA methylation markers

Early detection of asymptomatic disease Early diagnosis of symptomatic disease

positive margin negative margin poor or undifferentiated well or moderate no positive nodes positive nodes < 3 cm ≥ 3 cm p< Survival for Ductal Pancreas Adenocarcinoma Tumor Diameter Margin Status Lymph Node Status Histologic Grade

Early detection of small asymptomatic neoplasms may result in cure Best outcome: 79 patients wth small, asymptomatic, < 1 cm cancers 5- year survival 100% after surgery if PC limited to duct epithelium (CIS?) Ariyama 1997

What is the natural history of patients who present with symptoms and are ultimately diagnosed with pancreatic cancer? We do not have much quantitative information on the obstacles to diagnosis for patients with pancreatic cancer

When there are delays in diagnosis, what are their causes?

Chari et al, AJR 2004;182:897 Pancreatic CT abnormalities up to 18 months prior to a diagnosis of pancreatic cancer

How many patients would have a significantly improved outcome if they were optimally diagnosed as soon as symptoms presented?

Markers of Pancreatic Neoplasia What performance characteristics are needed for a(serum) molecular marker for the Diagnosis of pancreatic cancer

The performance characteristics of a marker often vary by population (disease stage, heterogeneity): Ca19-9 PC AmpCA CP islet ca controls JHU unpublished Sensitivity for resectable PC =65% (Sensitivity for unresectable PC=80%)

900 (TP)200 (FP) 100 (FN)800 (TN) DiseaseNo Disease Positive Negative Test Sensitivity: 90% Specificity: 80% (for cancer) PPV: 900/1100=81% NPV: 800/900=91% 1,000 1, Disease prevalence 50% (e.g. pancreatic mass)

182 (TP)360 (FP) 18 (FN)1540 (TN) DiseaseNo Disease Positive Negative Sensitivity: 90% Specificity: 80% (for resectable cancer) PPV: 182/542=34% NPV: 1540/1558=98% 1, Disease prevalence ~10%, e.g. mid-back pain, wt loss

What performance characteristics are needed for a molecular marker for Screening for pancreatic cancer?

General Population: Age 65: 5 year Risk PPV NPV Surveillance Epidemiology and End Result

18 (TP)396 (FP) 2 (FN)1584 (TN) DiseaseNo Disease Positive Negative Sensitivity:90% Specificity: 80% PPV: 18/414=4.3% NPV: 1584/81856=99.8% 1, Disease prevalence, 1%

New Onset Diabetics: 3 yr PC risk PPV NPV Chari et al. Gasto 2005

Family Hx PC 3 1 st -degree relatives: 3-yr PC risk PPV NPV Klein et al. Cancer Research 2004

PPV NPV Klein et al. Cancer Research 2004 Family Hx PC 2 1 st -degree relatives: 3-yr PC risk

Is this the right question to ask of our markers? What performance characteristics are needed for a molecular marker to Screen for pancreatic cancer?

What about the performance characteristics for a molecular marker of neoplastic precursors?

DiseaseNo Disease Positive Negative Test: Sensitivity: 95% Specificity: =90% (EUS or MRI) PPV: 95/105=91% NPV: 90/95=95% Strong Family Hx of PC, prevalence: 10% (IPMN)

Cancer of the Pancreas Screening (CAPS) clinical trials Who are we screening? Asymptomatic High risk individuals with a strong family history of pancreatic cancer and certain germline mutation carriers CAPS1:1999 CAPS2: 2001 CAPS3: 2006 CAPS4: 2008

Familial PC Screening Programs PopnScreening Tests Diagnostic Yield (IPMN/PC) Canto, CGH 2004,n=36 FPC (> 3) PJS EUS 5.8% Canto, CGH 2006,n=78 FPC (> 3) PJS EUS + CT10.2% Kurtz, DDW 2007,n=66 FPCCT/MRI +/- EUS 7.6% Poley, DDW 2007,n=46 FPC, PJS, FAMM, BRCA1/2 EUS 23.9% Other studies ongoing, eg. Brentnall et al (Seattle), Europac, U Pitt, Zubarik et al, (Vt)

Cancer of the Pancreas Screening Study (CAPS) 3 CAPS 3 – 1 st national American multicenter screening study  EUS/CT/MRI + biomarkers (juice)  Hopkins, Mayo, MDACC, Dana Farber, UCLA    lizst.onc.jhmi.edu/caps3

CAPS 4 Single center, long-term screening and surveillance (V foundation) Evaluate expanded eligibility –1 FDR, 1 SDR (eg. parent and grandparent) –BRCA2 mutation carriers Biomarker discovery

3 months 10 mm 12 months 18 mm baseline

Lobular CP like changes on EUS

Extensive PanIN  Lobulocentric atrophy Brune et al, AJSP, 2006

Is the identification of IPMNs and PanINs in asymptomatic individuals justified when we have not proven that surveillance of these lesions leads to improved outcome?

What molecular markers are on the horizon and can they help identify cancer or advanced neoplasia?

Molecular alterations in pancreatic cancer DNA: Somatic mutations Aberrant DNA methylation Chromosomal losses/gains RNAs: RNAs and microRNAs Proteins Peptides, glycopeptides Other eg. Autoantibodies Infiltrating pancreatic ca

Normal Duct PanIN 1APanIN 1B PanIN 2PanIN 3 Invasive AdenoCa Intraductal Papillary Mucinous Neoplasm (IPMN) Mucinous Cystic Neoplasm (MCN) Cystic Lesion AdenomaCarcinoma in situ Invasive AdenoCa

Research Activity Time Candidate Markers Pancreatic cancer research: Era of systematic discovery Translational Evaluation of markers 100% 0% Systematic Discovery (“Omics”)

The Pancreatic Cancer Genome

Data figure on the pc genome Number of somatic mutations in pancreatic cancer

Walter et al, Cancer Biol Ther, 2008 Gains Losses Pancreatic cancer chromosomal gains + losses

Quantifying mutant KRAS in Pancreatic juice: LigAMP Shi et al, Cancer Biol Ther, 2008 PC CP

Discovering the cancer methylome Methylome = genome wide DNA methylation patterns

Chr1 Chr2 Chr3 Chr4 Chr5 Chr6 Chr7 Chr8 Chr9 Chr10 Chr11 Chr12 Log ratio

Hong et al, Modern Path in press Aberrant DNA methylation in IPMNs %

Quantitative Methylation analysis of ERCP Brushings of common bile duct strictures

QMSP ≥1 gene + 3 gene panel, >3% conc.n Sens (CI)Spec (CI)Accuracy (CI) Pancreatic adenocarcinoma (58-84) a 86.4 (7-24) 81 (73-88) i Biliary tract cancer1080 (49-94) b 86.4 (7-24)86 (76-92) Cytology Pancreatic adenocarcinoma (14-34) c 100 (95-100) 69 (60-77) Biliary tract cancer1030 (11-60) d 100 (95-100)92 (84-96) Cytology + QMSP Pancreatic adenocarcinoma4176 (61-76) e 86.4 (7-24)82 (74-88) h Biliary tract cancer1090 (60-96) f 86.4 (7-24)88 (79-94) QMSP of biliary and Pancreatic duct Brushings performed to diagnose strictures Parsi et al, Clin Gastro Hep, 2008

Pancreas juice sampling for markers

Quantifying pancreatic juice DNA methylation alterations 5 gene panel, quantified by QMSP, CAPS2 study population Cancer Res 2006:66:1208

Marker Discovering Pancreatic cancer expression patterns

Clin Cancer Res 2006;12:442 Candidate pancreatic cancer markers: Serum Macrophage inhibitory cytokine-1 (MIC-1) PC=pancreatic cancer CP=chronic pancreatitis Nl=normal ELISA

MicroRNA alterations in pancreatic cancer Hahn et al, Oncogene 2007;264442